Carvone’s Hypoglycemic and Hypolipidemic Potent Activity Via Regulation Insulin-Induced Genes in Diabetic Hyperlipidemic Rats

Abstract

Carvone is a monoterpene and component of many essential oils from medicinal plants. Our research intended to evaluate the therapeutic efficacy of carvone in the handling of diabetes and hyperlipidemia in alloxan-induced type 2 diabetics. Alloxan (120 mg/kg) was administered intraperitoneally to male albino rats to induce diabetes as a single dose after diabetes, followed by two weeks of feeding the hypercholesterolemic atherogenic diet to develop hyperlipidemia. For one month, carvone (50 mg/kg) was administered orally to diabetic hyperlipidemic rats. Metformin, a common oral hypoglycemic medication, and atorvastatin, a standard oral hypolipidemic drug, were used to compare the findings. Our findings showed a reduction in blood glucose levels, low-density lipoprotein, cholesterol, and triglyceride. Upon administration of carvone, the encoded proteins (Insulin-induced gene-1and insulin-induced gene-2) were evaluated, which prevent Sterol regulatory-element binding proteins from being proteolytically activated. These transcription factors promote cholesterol and fatty acid production in the liver and other tissues. Histopathological alterations in pancreatic tissue were among the biomarkers chosen for hypoglycemic and hypolipidemic examinations. These findings suggested that carvone may be hypoglycemic and hypolipidemic potent activity by regulating insulin-induced genes.